Methods: Adult patients with septic shock by the Sepsis-3 classification due to lung infection or primary bacteremia or acute cholangitis are screened using two consecutive measurements of ferritin and of HLA-DR/CD14 co-expression for MALS (ferritin above 4,420 ng/ml) or immunosuppression (HLA-DR/CD14 less than 30%) and randomized into immunotherapy with either anakinra (targeting MALS) or recombinant IFNγ (targeting immunosuppression) and into placebo treatment. The gene discussed is CD14; the disease is acute cholangitis.